When should the MELD‑Na score be used to determine transplant eligibility for hepatocellular carcinoma, and in which situations is it not practical?

MELD-Na Score for Hepatocellular Carcinoma Transplant Eligibility

HCC is a specific exception to standard MELD-based allocation, requiring additional priority points rather than relying on the MELD-Na score alone for transplant eligibility determination 1.

When MELD-Na Should Be Used for HCC

Primary Role: Assessing Underlying Liver Dysfunction

• MELD-Na evaluates hepatic reserve and short-term mortality risk in HCC patients with cirrhosis, but does not determine transplant eligibility based on tumor characteristics 2
• Use MELD-Na (or standard MELD) to assess whether patients can tolerate the transplant procedure itself, particularly when MELD >30, where perioperative mortality and morbidity risks become substantial 1
• A MELD score ≥15 is recommended for listing patients with end-stage liver disease for transplant, as patients with MELD ≤14 have lower 1-year survival with transplantation compared to without 1

Supplementary Prognostic Information

• MELD-Na provides complementary prognostic data at HCC diagnosis and may help stratify risk when combined with tumor staging 3, 4
• The MELDNa variant demonstrates superior prognostic accuracy compared to standard MELD, MELD-Na, or ReFit MELDNa for HCC patients regardless of treatment strategy 3

When MELD-Na Is NOT Practical for HCC

Tumor-Based Allocation Takes Priority

HCC patients receive exception points (additional MELD points) independent of their laboratory MELD score to prioritize them based on tumor characteristics rather than liver dysfunction severity 1. This system exists because:

• Standard MELD underestimates mortality risk in HCC patients with compensated cirrhosis who face tumor progression rather than liver failure as their primary threat 2
• Waiting list time-dependent points are added to laboratory MELD for HCC patients, with additional points based on tumor size, number of nodules, AFP level, waiting time, and response to downstaging 1

Specific Situations Where MELD-Na Is Inadequate

1. Patients Meeting Milan Criteria

• Single tumor ≤5 cm or 2-3 tumors all ≤3 cm without vascular invasion 5, 6
• These patients receive standardized exception points (e.g., 22 MELD exception points in UNOS system) regardless of their actual laboratory MELD 7

2. Patients with Modest Expansion Beyond Milan

• Selected patients beyond Milan criteria (e.g., UCSF criteria) may be considered for transplant with exception points if downstaged successfully 8
• Patients with AFP >1,000 ng/ml should NOT be considered for transplantation regardless of MELD score, unless liver-directed therapy produces sustained AFP decline 8

3. Non-Cirrhotic HCC

• Milan criteria and MELD-based systems are not applicable to HCC in non-cirrhotic livers 6
• These patients may be considered for transplant based on absence of macrovascular invasion and extrahepatic spread, not MELD scores 6

4. Very Low MELD Scores

• Patients with Child-Pugh A cirrhosis and early HCC often have MELD <15, yet clearly benefit from transplantation due to tumor biology rather than liver dysfunction 9, 5

Critical Caveats

MELD-Na Limitations in HCC Context

• Does not account for portal hypertension, which significantly impacts outcomes but isn't captured in the score 2
• Serum creatinine (MELD component) is unreliable in cirrhotic patients and may not reflect true renal function 2
• Clinical assessments of ascites and encephalopathy are excluded from MELD but remain important for overall prognosis 2

Practical Algorithm for HCC Transplant Evaluation

Step 1: Confirm HCC diagnosis and stage tumor burden (imaging ± biopsy)

• Use dynamic CT or MRI with arterial enhancement and washout 6
• Assess for extrahepatic disease and macrovascular invasion 8

Step 2: Determine if patient meets transplant criteria based on tumor characteristics

• Within Milan criteria → eligible for exception points
• Beyond Milan but within expanded criteria → consider downstaging
• AFP >1,000 ng/ml → generally contraindicated unless sustained decline achieved 8

Step 3: Assess liver function to determine transplant candidacy and timing

• Calculate MELD-Na to evaluate hepatic reserve
• Child-Pugh C patients should receive only supportive care unless tumor is within Milan criteria and MELD-based allocation allows consideration 9, 5
• MELD >30 warrants careful assessment of perioperative mortality risk 1

Step 4: Apply exception points system per regional allocation policy

• Exception points standardized by country/region
• Consider tumor size, number, AFP, waiting time, and downstaging response 1

When to Prioritize Laboratory MELD-Na Over Exception Points

• Patients with decompensated cirrhosis (MELD >20-25) and small HCC may have higher short-term mortality from liver failure than tumor progression 3
• In these cases, the laboratory MELD-Na may already provide sufficient priority without exception points